A practical reference on research peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
DCI John Caldwell, an off duty Police Service of Northern Ireland officer, is injured in Omagh after being shot by suspected New IRA gunman. 23 February Labour leader Sir Keir Starmer outlines the five key issues that his party will focus on during the run up to the 2024 general election: higher economic growth, clean energy, improving the NHS, reforming the justice system, and raising education standards. Environment Secretary Thérèse Coffey, commenting on the vegetable shortage, tells MPs "we anticipate the situation will last about another two to four weeks". Three men are arrested in relation to the previous evening's shooting of DCI John Caldwell. 24 February The British Medical Association announces that junior doctors in England will begin a three-day strike on 13 March. An earthquake measuring 3.7 magnitude strikes Brynmawr, Blaenau Gwent at 11.59pm. COVID-19 in the UK: Office for National Statistics data for the week up to 14 February indicates COVID-19 cases continued to rise in England, Scotland and Wales, but remained uncertain in Northern Ireland. In England, the estimated number of people testing positive for COVID-19 was 1,223,000 (or 2.18% of the population and around 1 in 45 people). 27 February New Transgender Policy Guidance for England and Wales came into force on 27 February 2023 under which transgender women offenders would no longer be housed in women's prisons if they had male genitalia or had committed sex crimes.
=== Pirkle-type CSP === Pirkle and co-workers pioneered the development of a variety of CSPs based on charge-transfer complexation and simultaneous hydrogen bonding. These phases are also referred to as Brush-type CSPs. The Pirkle phases are based on aromatic π-acid (3,5-dinitrobenzoyI ring) and π- basic (naphthalene) derivative. In addition to π-π interaction sites, they have hydrogen-bonding and dipole-dipole interaction sites provided by an amide, urea or ester functionality. Strong three-point interaction, according to Dalgleish's model, enables enantioseparation. These phases are classified into π-electron-acceptor, π-electron-donor or π-electron acceptor-donor phase. A number of Pirkle-type CSPs are commercially available. They are used most often in the normal phase mode. The ionic form of the DNPBG (3,5-dinitrobenzoyl-phenylglycine) CSP has been successfully employed to achieve separation of racemic propranolol in biological fluid. Many compounds of pharmaceutical interest including enantiomers of naproxen and metoprolol has been separated using Pirkle CSP.
=== Radioprotectors === A radioprotector is a pharmacon that, when administered, selectively protects healthy cells from the toxic effects of ionizing radiation. The first work with radioprotectors began as part of the Manhattan Project, a military research project to develop and build an atomic bomb.
=== Metabolic pathways === Genomic analysis indicates that "Ca. M. multicellularis" has the potential to use both autotrophic and heterotrophic pathways. For autotrophic growth, it utilises the Wood–Ljungdahl pathway (also known as the reductive acetyl-coenzyme A pathway) for carbon fixation. For heterotrophy, it is able to use small organic molecules including acetate, propionate, and succinate as carbon donors and/or electron sources. "Ca. M. multicellularis" has also been found to contain a complete glycolysis pathway, a full TCA cycle and group-1 nickel-iron hydrogenases coupled to oxidative phosphorylation. As found in SCM sequencing, the consortium exhibits both genetic and metabolic differentiation. The use of nano-scale secondary ion mass spectrometry (NanoSIMS) and bioorthogonal noncanonical amino acid tagging (BONCAT) demonstrated that anabolic activity and protein synthesis is not uniform across the organism. The most active regions of protein synthesis were found to be concentrated around the acellular centre. A 2024 study suggests the potential for an internal division of labour, with certain cells metabolising specific substrates and transferring them to surrounding cells by membrane vesicles.
Sources: en.wikipedia.org
27 October – Former Health Secretary Alex Neil calls for an urgent review of the use of WhatsApp by government following revelations that National Clinical Director Jason Leitch deleted messages on a daily basis during the pandemic; he also says that many government ministers did not understand the rules for using the app. 28 October – Ash Regan, who stood as a candidate in the 2023 SNP leadership election, defects to the Alba Party after becoming disillusioned with what she describes as the SNP's "wavering commitment" to Scottish independence. 29 October – First Minister Humza Yousaf says he has made contact with his in-laws trapped in Gaza for the first time since a communications blackout two days earlier. The Sunday Mail reports that WhatsApp messages relating to the COVID-19 pandemic sent by First Minister of Scotland, Nicola Sturgeon, were manually deleted from her phone. 30 October – First Minister Humza Yousaf says that allegations he deleted WhatsApp messages relating to the COVID-19 pandemic are "certainly not true". 31 October – Scotland's Deputy First Minister, Shona Robison, confirms that Scottish Government will hand 14,000 electronic messages relating to the pandemic to the UK COVID-19 Inquiry.
Ernst on developing the first two-dimensional NMR experiments, and established the nuclear Overhauser effect as a convenient way of measuring distances within proteins. This research later led to the complete assignment of resonances for among others the bovine pancreatic trypsin inhibitor and glucagon. In October 2010, Wüthrich participated in the USA Science and Engineering Festival's Lunch with a Laureate program where middle and high school students will get to engage in an informal conversation with a Nobel Prize–winning scientist over a brown-bag lunch. Wüthrich is also a member on the USA Science and Engineering Festival's Advisory Board and a supporter of the Campaign for the Establishment of a United Nations Parliamentary Assembly, an organisation which campaigns for democratic reform in the United Nations. Wüthrich is a member of the Executive Advisory Board of the World.Minds Foundation, where he contributes to international dialogue on science, research, and innovation policy.
==== Physiological and metabolic consequences ==== OSA in adults is associated with a higher risk for cardiovascular morbidities, diabetes, hypertension, coronary artery disease and stroke – OSA might have a role in the etiology of these conditions. Those conditions may lead to increased mortality that an appropriate treatment for OSA may reduce. OSA is often linked with hypertension as it induces an increase in sympathetic activity that can lead to the elevation of blood pressure. The OSA-related hypercapnia has been suggested to be related to the development of hypertension. Treating the OSA may prevent the development of hypertension. The relationship between OSA and excess body weight is complex, as obesity is more prevalent amongst OSA patients but can also be a risk factor for the development of OSA – it accounts for 58% of adult cases. Thus, both OSA and obesity (when present) may work synergistically and lead to hyperlipidemia, diabetes, insulin resistance and other symptoms of the metabolic syndrome. The metabolic syndrome itself is often associated with OSA: 74–85% of OSA patients are diagnosed with it. CPAP therapy can lead to an improvement of some of the cardiovascular component of the metabolic syndrome while weight loss is also recommended for its positive effects on OSA consequences and metabolic dysfunctions. An intervention comprising exercise and diet is thus effective for the treatment of OSA as it positively impacts the severity of both obesity symptoms and OSA symptoms.
=== Non-medical use === Though not an approved drug, LGD-4033 (Ligandrol) has been sold on the black market as a designer drug in countries where it is classified as an illegal substance. Along with enobosarm (ostarine; GTx-024, S-22), andarine (GTx-007; S-4), and vosilasarm (RAD140; "testolone"), LGD-4033 is one of the most popular and common non-medically-used SARMs. Many products sold online that are purported to be LGD-4033 either contain none or contain other unrelated substances, and doses are also frequently not as labeled. Social media has played an important role in facilitating the widespread non-medical use of SARMs. On 23 October 2017, a nutritional supplement company in Missouri called Infantry Labs was warned by the FDA that the distribution of two of its products violated the Federal Food, Drug, and Cosmetic Act. One of the substances was LGD-4033. The company advertised as benefits of the LGD-4033: "increases in lean body mass and decrease in body fat" and "increases in strength, well being, as well as healing possibilities". The company mislabeled as "dietary supplements" what should have been "new drugs" or "prescription drugs" and were instructed to document the steps they would take in order to cease the violation. Also on 23 October 2017, the FDA sent a warning letter to a New Jersey company called Panther Sports Nutrition. The company's marketing approach for the product was similar to that of the Infantry Labs case, and the product was advertised as a "mass builder" and "physique enhancing agent".
Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. Specifically, it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship. It is given by an injection just under the skin of the thigh or abdomen. Common side effects include nausea, pain at the site of injection, and headache. It may also cause a temporary increase in blood pressure and decrease in heart rate after each dose, and darkening of the gums, face, and breasts. The medication is a peptide and acts by activating the melanocortin receptors. Bremelanotide was approved for medical use in the United States in 2019. It was developed by Palatin Technologies.
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.